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Abstract
The simultaneous application of ultrasound and the surfactant sodium lauryl sulfate (referred to as
US/SLS) to skin enhances transdermal drug delivery (TDD) in a synergistic mechanical and
chemical manner. Since full-thickness skin (FTS) and split-thickness skin (STS) differ in
mechanical strength, US/SLS treatment may have different effects on their transdermal transport
pathways. Therefore, we evaluated STS as an alternative to the well-established US/SLS-treated
FTS model for TDD studies of hydrophilic permeants. We utilized the aqueous porous pathway
model to compare the effects of US/SLS treatment on the skin permeability and the pore radius of
pig and human FTS and STS over a range of skin electrical resistivity values. Our findings
indicate that the US/SLS-treated pig skin models exhibit similar permeabilities and pore radii, but
the human skin models do not. Furthermore, the US/SLS-enhanced delivery of gold nanoparticles
and quantum dots (two model hydrophilic macromolecules) is greater through pig STS than
through pig FTS, due to the presence of less dermis that acts as an artificial barrier to
macromolecules. In spite of greater variability in correlations between STS permeability and
resistivity, our findings strongly suggest the use of 700-μm-thick pig STS to investigate the in
vitro US/SLS-enhanced delivery of hydrophilic macromolecules.
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1. INTRODUCTION
The simultaneous application of low-frequency ultrasound and the surfactant sodium lauryl
sulfate (referred to as US/SLS) to skin enhances transdermal drug delivery (TDD) in a
synergistic mechanical and chemical manner [1,2]. With the advance of US/SLS, as well as
of other TDD enhancement methods [3,4], it is now possible to transdermally deliver
therapeutic macromolecules (including proteins, vaccines, and drug delivery vehicles) in
significant amounts [5-7]. The delivery targets for these macromolecules are the Langerhans
cells in the epidermis or the blood capillaries just below the epidermis. In the case of
macromolecules, one must now consider the dermis as a potential artificial diffusion barrier
in in vitro TDD studies, regardless of the hydrophilicity of the macromolecule. The dermis
may act as a reservoir (i.e., a diffusion sink) for absorbed macromolecules due to steric
hindrance effects or interactions between the macromolecules and the dermal components
[8-10]. Therefore, split-thickness skin (STS) would be an attractive alternative skin model to
full-thickness skin (FTS) to reduce the barrier properties of the dermis and to more
accurately study the US/SLS-enhanced transdermal delivery of therapeutic macromolecules.
Yet, to our knowledge, all in vitro US/SLS studies have been carried out using the well-
established FTS model [11-17].
STS is typically prepared from full-thickness skin (FTS) using a dermatome, which removes
much of the dermis from FTS. Even though STS is a common skin model for in vitro TDD
studies, it is not at all clear that STS is a suitable skin model for the application of US/SLS.1
This is because US/SLS enhances skin permeability in a synergistic mechanical and
chemical manner [1,2], and since FTS and STS differ in the thickness of dermis acting as an
underlying mechanical support, FTS and STS may undergo different extents of skin
structural perturbation in response to the US/SLS treatment. In fact, the possibility that FTS
and STS could respond differently to the application of US motivated a previous
comparative study on US-treated skin models [18] that was completed before US was
combined with SLS to more effectively enhance skin permeability [1,19,20]. Since the US/
SLS treatment was found to be more effective than the previously used US treatment
[1,19,20], and since the US/SLS treatment is the currently used one in clinical applications
[21,22], a similar comparative study on US/SLS-treated FTS and STS is clearly needed.
With the above need in mind, our primary objective was to investigate whether US/SLS-
treated STS would be a suitable alternative to the well-established US/SLS-treated FTS
model. We chose to perform this comparative study on two pig skin models and three
human skin models: pig FTS (pFTS), 700-μm-thick pig STS (p700), human FTS (hFTS),
700-μm-thick human STS (h700), and 250-μm-thick human STS (h250). Note that the third
human skin model is the thinnest that we could consistently prepare using a dermatome, and
that 250-μm-thick pig STS was not studied because the coarse hair shafts left macroscopic
holes in the dermatomed pig skin. We utilized the aqueous porous pathway model to
compare the effects of US/SLS treatment on the skin permeability and the effective skin
aqueous pore radius of the hydrophilic transport pathways within these five skin models. In
this article, we will show that: (1) pig FTS and STS models exhibit similar US/SLS-
enhanced permeabilities and pore radii after US/SLS treatment, (2) human FTS and STS
models exhibit different permeabilities and pore radii after US/SLS treatment, and (3) a
comparison of the US/SLS treatment times for the skin models strongly suggests that
intrinsic differences within pig and human skin are contributing to the observed differences
in (1) and (2). We will also discuss the strengths and weaknesses of each skin model
1Note that the alternative protocols involving applying US/SLS to FTS and then partially removing the dermis to create STS are not
practically feasible. This is mainly because the skin must be clamped into a diffusion cell during the US/SLS treatment, resulting in a
partially compressed skin sample from which the STS preparation is difficult.
Seto et al. Page 2
J Control Release. Author manuscript; available in PMC 2011 July 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
investigated. In addition, we will provide two examples to compare pig STS to FTS for in
vitro US/SLS experiments in the case of gold nanoparticles (AuNPs) and quantum dots
(QDs), which serve as well-characterized, model hydrophilic macromolecular permeants.
Specifically, we will demonstrate that due to a thinner dermal layer, AuNPs and QDs diffuse
through STS in greater amounts compared to FTS. These results suggest that the use of pig
STS over FTS may be beneficial in future in vitro studies on the US/SLS-enhanced
transdermal delivery of hydrophilic macromolecules.
2. MATERIALS AND METHODS
2.1 Chemicals
14C-labeled sucrose in sterile water (600 mCi/mmol) was obtained from American
Radiolabeled Chemicals (St. Louis, MO). Phosphate buffered saline (PBS) tablets and SLS
solution (20 w/v% in water) were obtained from Sigma-Aldrich (St. Louis, MO). PBS was
prepared from PBS tablets according to the manufacturer’s instructions. Hionic-Fluor
scintillation cocktail was obtained from PerkinElmer (Waltham, MA). AuNPs, with a core
diameter of 4.6 ± 1.5 nm (mean ± SD) and a 11-mercapto-1-undecanesulphonate ligand
shell, were a gift from Professor Francesco Stellacci’s group at MIT (synthesized using a
published method [23]). Nitric acid (BDH, Aristar® Ultra grade), hydrochloric acid (BDH,
Aristar® Ultra grade), and certified gold and indium stock standards (BDH, Aristar® grade)
were obtained from VWR International (West Chester, PA). Deionized water dispensed
from a Milli-Q academic water purification system (Millipore, Bedford, MA) was used to
prepare all solutions.
2.2 Skin preparation
Human FTS (21–50 year old Caucasian back and abdominal skin, excised ≤12 hours
postmortem, shipped at −80°C) was obtained from the National Disease Research
Interchange (Philadelphia, PA) and stored at −80°C until use. Before each experiment, the
skin was thawed, the subcutaneous fat was removed with a razor blade, and excess hair was
trimmed with scissors. Female Yorkshire pig FTS (back and flank skin) was harvested
within an hour after sacrificing the 70-lb animal (purchased from E.M. Parsons & Sons,
Hadley, MA). The subcutaneous fat was removed, and the skin was sectioned into 1-inch
strips before storing at −80°C until use. Before each experiment, the skin was thawed and
excess hair was trimmed with scissors. After these preparations, the human and pig FTS
thicknesses ranged from 2–4 mm and 1–2.5 mm, respectively. Then, STS was prepared from
1-inch strips of FTS using an electric dermatome (Zimmer Orthopaedic Surgical Products,
Dover, OH). Next, the FTS or STS strips were sectioned and placed on top of a 150-μm
opening nylon mesh (Sefar Filtration, Depew, NY) for support. High vacuum grease (Dow
Corning, Midland, MI) was applied to 15-mm inner diameter standard Franz diffusion cells
(PermeGear, Hellertown, PA) in order to create a water-tight seal between the skin and the
diffusion cell. Finally, the skin was clamped into the diffusion cells. This experimental
protocol was approved by the Committee on Animal Care at MIT.
2.3 Measurement of skin electrical resistivity
The skin electrical resistivity, R, is a sensitive quantitative indicator of the structural state of
the skin [18,24,25]. R was measured according to a previously published method [13,18].
Briefly, a voltage was applied across the skin sample using two Ag/AgCl electrodes. The
skin electrical current was measured using a multimeter, and the skin electrical resistance
was obtained from the skin electrical current using Ohm’s Law (taking into account the
background resistance). The skin electrical resistance was multiplied by the skin area to
obtain the value of R. This method was used to: (1) check the initial structural state of the
skin – any skin sample with an initial R value of <50 kΩ·cm2 was considered damaged
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[26,27] and was discarded, (2) determine if the desired value of R had been reached during
US/SLS treatment, indicating that the desired extent of skin structural perturbation was
attained, and (3) determine the average value of R during the time period when the skin
permeability to sucrose was measured. The values measured in (3) were used in the analysis
described in Section 2.8.
2.4 US/SLS pre-treatment of the skin
Our protocol consisted of first pre-treating skin with US/SLS, and then carrying out a
passive sucrose permeation experiment for 26 hours to measure the US/SLS-enhanced
steady-state skin permeability to sucrose. For the first step of the protocol, US/SLS was
applied to the intact skin samples based on a previously published method [12], with the
following modifications: US, with the probe tip immersed in a coupling medium containing
1 w/v% SLS in PBS, was applied to the skin samples with a VCX 500 and a coupler probe
(Sonics & Materials, Newtown, CT) at the following typical US parameters [28]: frequency
- 20 kHz, intensity - 7.5 W/cm2, pulse length - 5 seconds on, 5 seconds off, and distance
between the probe tip and the skin - 3 mm. The US intensity was calibrated using
calorimetry [29]. The US/SLS treatment was stopped at least every two minutes to
determine if the desired R value was attained and to replace the coupling medium (to
minimize thermal effects [2]). The aim of the US/SLS treatment was to attain a range of R
values, corresponding to a range in the extent of skin structural perturbation. The maximum
and minimum R values attained were 40 kΩ·cm2 (corresponding to a minimal amount of
US/SLS treatment) and 0.4 kΩ·cm2 (within the range of R values attained using an FDA-
approved ultrasonic skin permeation device in clinical applications [22,30]), respectively.
2.5 Measurement of skin permeability to sucrose
After applying US/SLS treatment to skin (see Section 2.4), the skin permeability to sucrose
was measured. Sucrose was previously determined to be a reliable hydrophilic probe
molecule for using the porous pathway model to estimate the skin pore radius [31]. US/SLS-
treated skin samples were remounted into clean, dry Franz diffusion cells. 12 mL of PBS
was added to the receiver chambers, and 2 mL of donor solution containing 14C-labeled
sucrose in PBS was added to the donor chambers. Typical donor solution concentrations
ranged from 5 μCi/mL for the skin samples with R values of 40 kΩ·cm2 to 0.3 μCi/mL for
the skin samples with R values of 0.4 kΩ·cm2. Note that the donor solution concentrations
were chosen such that the amount of 14C in the receiver solution aliquots was at least ten
times that in PBS (background). Diffusion experiments were conducted at room temperature
(25°C), and the receiver solutions were magnetically stirred at 400 RPM.
Samples were withdrawn from the diffusion cells during the steady-state domain at five
predetermined time points from 18 – 26 h (the attainment of steady-state diffusion is
discussed in Section S1). At each time point, R was measured, 200-μL aliquots of the donor
solutions were withdrawn, and 400-μL aliquots of the receiver solutions were withdrawn.
Each receiver solution aliquot was immediately replaced with an equal volume of PBS.
After mixing each aliquot with 5 mL of scintillation cocktail, the radioactivity of the aliquots
was measured using a Tri-Carb 2810TR liquid scintillation analyzer (PerkinElmer,
Waltham, MA).
Finally, the skin permeability to sucrose, P, was calculated at steady-state, sink conditions
using the following well-known equation:
(1)
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where V is the volume of PBS in the receiver chamber, A ( = 1.77 cm2) is the permeation
area, Cd is the average sucrose concentration in the donor chamber, and (ΔC/Δt) is the
steady-state rate of change in sucrose concentration in the receiver chamber (taking into
account the replacement of the receiver aliquots and the background radioactivity) [28]. The
experimental conditions for which Eq. (1) is valid are discussed in Section S1.
2.6 Calculation of the effective skin aqueous pore radius
The main assumption of the aqueous porous pathway model is that a hydrophilic permeant
traverses the skin via the same aqueous porous pathway as the conducting ions in the
electrolyte solution surrounding the skin (in PBS, the dominant ions are Na+ and Cl−) [31].
The porous pathway model was developed in order to quantify the effects of steric hindrance
resulting from the radii of the permeant and of the conducting ions relative to the effective
skin aqueous pore radius, rpore [31]. Accordingly, rpore can be determined by comparing the
hindered transdermal diffusion of the permeant (related to P) to that of the conducting ions
(related to R) [31].
Based on the porous pathway model [31], the relationship between P and R is given by:2,3
(2)
where C is defined as follows [31]:
(3)
where k is the Boltzmann constant, T is the absolute temperature, z is the electrolyte valence,
F is the Faraday constant, cion is the electrolyte molar concentration, e0 is the electronic
charge,  is the diffusion coefficient of solute i (permeant (p) and ion) at infinite dilution,
H(λi) is the diffusive hindrance factor of solute i, and λi is the ratio of the radius of solute i,
ri, and rpore (that is, λi = ri/rpore). In previous applications of the porous pathway model
[12,13,18,31-35], H(λi) was evaluated using the Renkin equation for λi < 0.4 as follows:
(4)
The hydrodynamic theory of hindered transport has advanced since the Renkin equation was
first introduced in 1954. Here, we make use of a more accurate expression for H(λi)
developed recently. Specifically, for λi ≤ 0.95, H(λi) is given by [36]:
(5)
Note that C in Eq. (3) is a function of a single skin structural parameter, rpore (through λi =
ri/rpore in H(λp)/H(λion)), as well as of other parameters that are not intrinsic to the skin
2The logarithmic form is used so that the regressed slopes and intercepts (see Section 2.8) are of the same order of magnitude.
3A few modifications to Eq. (2) have been reported in the literature [12,33,34]; however, these are not necessary for the purpose of
this study.
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structure. Furthermore, by evaluating Eq. (3) for various values of rpore, one finds that log C
increases (i.e., becomes less negative) as rpore increases.
For a log P – log R data set, each data point was extrapolated to the y-axis using a
theoretical slope value of −1 (see Eq. (2)) to calculate log C. From the extrapolated log C
values, the average log C value and associated 95% confidence interval (CI) were
calculated. Finally, rpore was determined from the average log C value using Eq. (3), Eq. (5),
and the parameter values listed in Section S2. The endpoints of the 95% CI for rpore were
calculated using the endpoints of the 95% CI for log C.
2.7 US/SLS-enhanced transdermal delivery of AuNPs
2.7.1 Transdermal delivery of AuNPs—Pig FTS and STS samples were pre-treated
with US/SLS (as described in Section 2.4) to attain R values of 0.8–1.2 kΩ·cm2. Then, the
US/SLS-treated skin samples were remounted into clean, dry Franz diffusion cells. 12 mL of
PBS was added to the receiver chambers, and 0.3 mL of the donor solution (0.1 w/v% AuNP
in water) was added to the donor chambers. Diffusion experiments were conducted for 24 h
at room temperature (25°C), and the receiver solutions were magnetically stirred at 400
RPM.
At the end of each diffusion experiment, the receiver solution and the skin sample were
collected. To minimize interference with the ICP-MS analysis of trace metals (see Section
2.7.2), the PBS salts were dialyzed out of the receiver chamber solution using a SnakeSkin
3500 MWCO regenerated cellulose membrane (Pierce Biotechnology, Rockford, IL) that
was placed in a stirred beaker of deionized water. The beaker was recharged with fresh
water three times over a period of 24 h. From the skin sample, the skin area exposed to US/
SLS pre-treatment and passive AuNP diffusion was isolated; then, the epidermis was
mechanically separated from the dermis [37]. Finally, the dialyzed receiver solution and the
dermis were analyzed by ICP-MS as described in Section 2.7.2.
2.7.2 Quantification of AuNPs by ICP-MS—Inductively coupled plasma-mass
spectrometry (ICP-MS) was performed using a PlasmaQuad 2+ Quadrupole Mass
Spectrometer (Fisons Instruments, Merrimac, MA) to quantify the amount of Au in various
samples, based on a previously published method [38]. Briefly, the receiver solutions and
dermis samples (see Section 2.7.1) were digested under reflux by the addition of aqua regia
in polyfluor alkoxy (PFA) vials (Savillex, Minnetonka, MN) for 16 h at 110-120°C. Each
acid digestion sample was then diluted using 1% nitric acid. To ensure the accuracy and
precision of the technique, each sample was spiked with a standard indium (115In) salt
solution prior to injection into the ICP-MS system. Calibration plots were generated using
Au standards.
2.8 Statistical analysis
A linear regression was fitted to the log P – log R data set for each skin model considered.
The regression parameters were subjected to an analysis-of-variance (ANOVA) and an
analysis-of-covariance (ANCOVA) [39] as discussed in Sections 3.1 and 3.2. Two-sample,
two-tailed t-tests assuming unequal variances were used to compare log C values, US/SLS
treatment times, Au amounts, and Cd amounts. In all analyses, p values < 0.05 were
considered to be statistically significant.
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3. RESULTS AND DISCUSSION
3.1 Log P – log R correlations are well-described by the porous pathway model
Fig. 1 shows the experimental log P – log R correlations obtained for the five skin models
investigated, and Table 1 lists the log P – log R linear regression parameters. Table 1 shows
that the regressed slopes for all five skin models are not significantly different from −1. In
addition, the r2 values of the regressions are within the expected range reported in the
literature [31,40], and ANOVAs showed that the regressions are statistically significant (the
linear regressions “fit” the data, or the observed variations in P are explained by the linear
log P – log R correlations).
Since the regressed slopes are −1 and the linear regressions are statistically significant, two
conclusions can be drawn. First, our findings indicate that within the range of US/SLS
treatment conditions examined, the five skin models considered respond to US/SLS in a
predictable manner. Specifically, the transdermal transport of sucrose through the five US/
SLS-treated skin models is well-described by the porous pathway model. Therefore, the
porous pathway model can be applied to compare the structural parameters of the
hydrophilic transport pathways within each of the five skin models, which is discussed in
Section 3.2. Second, our findings indicate that within each skin model investigated, rpore
does not vary significantly over the range of R values attained using US/SLS treatment,
which is consistent with earlier findings (see Section S3 for additional discussion).
3.2 Comparison of log P – log R correlations among skin models
To compare the extent of structural perturbation within each US/SLS-treated human skin
model, we first carried out a statistical comparison of the regressed slopes and intercepts.
For hFTS, h700, and h250, ANCOVAs showed that there is no significant difference among
the slopes of the three regression lines, but that the intercepts are significantly different.
Pairwise t-tests further showed that the log C values for these three human skin models are
significantly different. Recall that log C increases as rpore increases (see Section 2.6).
Physically, these results indicate that of the three human skin models, h250 undergoes the
largest extent of structural perturbation (resulting in the largest rpore value 4), while hFTS
undergoes the smallest. These results strongly suggest that dermal thickness is significant
during the in vitro US/SLS application to human skin.5 Therefore, while all three human
skin models investigated react to US/SLS in a manner that is well described by the porous
pathway model, the three human skin models considered are not interchangeable.
Turning our attention next to pFTS and p700, the statistical analysis described above
showed that neither the slopes nor the intercepts of the two regressions are significantly
different; therefore, the regression lines coincide. Subsequently, a t-test showed that there is
no significant difference among the log C values (see Table 1) for pFTS and p700. This
result implies that there is no significant difference among the rpore values.4 Based on the
results of the statistical comparison of the regressed slopes, regressed intercepts, and log C
values for pFTS and p700, we conclude that there is no significant difference between the
intrinsic structural parameters of these two pig skin models, which are therefore comparable.
This indicates that the hydrophilic transport pathways within pFTS and p700 undergo
similar extents of structural perturbation in response to the US/SLS treatment. This is an
important finding that suggests that p700 may be utilized as an alternative skin model for in
vitro studies of the US/SLS-enhanced transdermal delivery of hydrophilic permeants. Our
4The corresponding rpore values are reported in Section S2.5For a discussion on why the dermal thickness is not significant during the passive sucrose permeability experiments, see Section S4.
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results further indicate that dermal thickness is not as significant during the in vitro US/SLS
application to pig skin compared to human skin.
Interestingly, the observed difference in the results for the pig and human skin models is
reflected in the US/SLS treatment times for the skin models (see Table 2). The treatment
times for pFTS and p700 are not significantly different, while the treatment times for the
human skin models vary with skin thickness. Notably, there is a significant difference
between the US/SLS treatment times for h700 and p700, which strongly suggests that
intrinsic differences within pig and human skin (e.g., differences in dermal elastic fiber
content [42]) are contributing to the differences in the results for pig and human skin. It is
important to note that although pig and human skin are similar, they also display significant
differences, as outlined in [42].
In comparing the r2 values for the five skin models, note that those associated with STS are
smaller than those associated with FTS (see Table 1). We attribute this difference to the
greater variability in tension that one can experimentally impart onto STS (since it is thinner
than FTS) when mounting skin into a diffusion cell. It has previously been proposed that
skin permeability is affected by lateral strain in the skin [43]. Furthermore, the elasticity of a
biomaterial (such as skin) is an important property that affects ultrasonic cavitation bubble
dynamics and microjet formation in the fluid surrounding the biomaterial [44]. Therefore,
variability in skin tension likely translates into variability in the mechanism of action of US/
SLS on the skin, including more variability in the STS data. Additional experiments would
be needed in order to test this hypothesis. In future studies, one should be cognizant of skin
tension when mounting skin into a diffusion cell. We suggest that the development of a
procedure to mount STS into a diffusion cell with consistent skin tension may reduce the
observed variability in the STS data.
3.3 US/SLS-enhanced delivery of AuNPs is greater through p700 than through pFTS
Our findings reported in Section 3.2 suggest that p700 can be considered to be an alternative
skin model to pFTS. To illustrate why STS may be preferred over FTS in in vitro
experiments in the case of macromolecules, we used gold nanoparticles (AuNPs) as well-
characterized, model hydrophilic macromolecular permeants and compared their US/SLS-
enhanced transdermal delivery through pFTS and p700. In in vitro transdermal delivery
experiments, hydrophilic molecules that permeate through the skin are ordinarily quantified
in the receiver solution [45] because the dermis is not considered a significant barrier for
these drugs. However, as we proposed in this work, the dermis can also act as a barrier to
hydrophilic macromolecules. Accordingly, the Au, present in the core of the AuNP studied,
was analyzed both in the receiver solution and in the dermis.
Between pFTS and p700, there was no significant difference in the total amount of Au found
in the dermis and the receiver solution (see Fig. 2a), which indicates that the total amounts
of AuNPs penetrating past the epidermis (the major diffusion barrier to hydrophilic
permeants) over 24 h are similar. This finding is consistent with our conclusion that pFTS
and p700 undergo similar extents of structural perturbation in response to the US/SLS
treatment (see Section 3.2). Interestingly, the fraction of AuNPs penetrating past the
epidermis but remaining in the dermis after 24 h was significantly larger when pFTS was
used (see Fig. 2b). This suggests that the thicker dermis in pFTS acts as a greater
transdermal diffusion barrier to the AuNPs, even though the AuNPs are hydrophilic. We
speculate that the dermis may act as a reservoir (i.e. a diffusion sink) for absorbed
macromolecules due to steric hindrance effects or interactions between the macromolecules
and the dermal components [8-10], or that there may be a longer lag time for
macromolecular diffusion through the thicker FTS dermis (which would support the
hypothesis that the dermis acts as an artificial barrier to hydrophilic macromolecules).
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We repeated the experiments described in this section with quantum dots as a second
hydrophilic macromolecular permeant and obtained similar results (see Section S5).
3.4 Strengths and weaknesses of the skin models investigated
In this section, we discuss the strengths and weaknesses of the skin models investigated.
Excised human skin is considered the “gold standard” for in vitro transdermal studies.
However, it is difficult to obtain regularly. Pig skin is a common animal skin model used in
in vitro transdermal studies, particularly in US/SLS studies [28]. Excised pig skin is easier
and cheaper to obtain than excised human skin, and the US/SLS treatment time for pig skin
is shorter than that for human skin (see Table 2). Based on this comparison, pig skin is
preferred over human skin.
Next, we compare FTS and STS. In the general transdermal field, STS is typically favored
over FTS [46]. However, all previous in vitro US/SLS studies have been carried out with
FTS [11-17], probably because STS had not been evaluated as a suitable in vitro skin model
for US/SLS studies. One weakness of FTS is that its thickness varies with the location of
skin procurement and the method used to remove the subcutaneous fat. The thickness of
STS is much more uniform than that of FTS. However, there is more variability in the
permeability data of US/SLS-treated STS (see the r2 values in Table 1) compared to that of
FTS. As discussed in Section 3.2, this variability may be minimized by mounting STS into a
diffusion cell with consistent skin tension. If the variability cannot be adequately minimized,
then one may need a larger number of replicates in a study using STS.
The choice of using STS or FTS depends on the final purpose of the study and on the
permeant quantification methods available, including whether dermis solubilization is
required to determine the amount of delivered permeant. It is generally easier to quantify the
amount of permeant in the receiver solution than in the dermis because the sample collection
is simpler and no tissue solubilization or extraction is required. If dermis solubilization is not
required, then the diffusion cell can be sampled at more than one time point, and the skin
permeability (as defined in Eq. (1)) and absorption kinetics can be measured. Therefore, in
spite of greater variability in the STS permeability data, one may choose to use STS to: (1)
obtain a larger amount of delivered permeant into the receiver chamber solution for easier
quantification (as shown in Fig. 2c), or (2) reduce the permeant donor concentration in order
to obtain the same amount of permeant in the receiver solution that one would obtain using
FTS, thereby reducing the amount and cost of material required for a study. On the other
hand, if the amount of permeant in the receiver solution is below the limit of quantification
for a desired method, then permeant quantification in the dermis using tissue solubilization
may be required. In this case, it is beneficial to use p700 over pFTS because the dermis
thickness is less variable (note that in Fig. S1, the QD amounts in p700 were less variable
than in pFTS). The above issues are particularly important in the case of hydrophilic
macromolecules, which pass through skin in low amounts and may not attain steady state
transdermal diffusion within 24 h.
If one wishes to obtain US/SLS-enhanced STS permeabilities that are not significantly
different than those obtained using FTS, our findings suggest the use of p700 as an
alternative skin model to pFTS. Additional experiments would be needed to investigate the
effects of US/SLS on pig STS models thinner than 700 μm. Regarding human STS, other
US/SLS conditions or human STS models thicker than 700 μm may be evaluated.
4. CONCLUSIONS
We compared the log P – log R correlations between pig and human FTS and STS in the
context of the aqueous porous pathway model, which was utilized to characterize the extent
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of structural perturbation of the hydrophilic transdermal transport pathways in response to
US/SLS treatment. For the US/SLS conditions and the range of R values considered, US/
SLS enhances P in each skin model in a predictable manner that is well-described by the
porous pathway model. The key result of our investigation is that pFTS and p700 respond
similarly to US/SLS, while hFTS, h700, and h250 respond differently to US/SLS. The
significant difference in US/SLS treatment times for p700 and h700 strongly suggests that
the difference in the results for pig and human skin is due to intrinsic differences within pig
and human skin. In comparing FTS and STS, we have shown that STS permeability data
may be more variable, but the thicker dermis in FTS acts as a greater transdermal diffusion
barrier to macromolecules (demonstrated using AuNPs and QDs as model hydrophilic
macromolecular permeants). Because the dermis acts as an artificial diffusion barrier, and
pig skin is more readily obtained and responds faster to the US/SLS treatment compared to
human skin, our findings strongly suggest the use of p700 for future in vitro studies on the
US/SLS-enhanced transdermal delivery of hydrophilic permeants (particularly, hydrophilic
macromolecules).
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Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.
Comparison of the experimental log P – log R correlations: (a) hFTS, n = 36, (b) h700, n =
44, (c) h250, n = 34, (d) pFTS, n = 47, and (e) p700, n = 35. Each data point represents one
experiment. The solid lines represent the linear regressions fitted to each data set. The
statistical parameters associated with the linear regressions are listed in Table 1.
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Fig. 2.
Quantification of Au in the dermis and in the receiver solution after 24 h of AuNP diffusion
through Clearing the Epidermis US/SLS-treated pFTS and p700. (a) Total amount of Au
found in the dermis and receiver solution, indicating the total amount of AuNPs penetrating
past the epidermis. (b) Fraction of AuNPs penetrating past the epidermis but remaining in
the dermis. (c) Amount of Au found in the receiver solution. The amounts found in pFTS
and p700 are not significantly different in (a) but are significantly different in (b) and (c).
Data shown are the mean ± SD of n replicates; n = 4 for pFTS, n = 5 for p700.
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Table 1
Statistics for the log P – log R data set for each skin model.
Skin
Type
Linear Regression Parameters
log Ca,c
Slope a,b Intercept a r2
hFTS −1.08 ± 0.10 −2.99 ± 0.09 0.93 −3.05 ± 0.14
h700 −1.04 ± 0.23 −2.88 ± 0.20 0.66 −2.91 ± 0.36
h250 −1.09 ± 0.27 −2.63 ± 0.20 0.68 −2.69 ± 0.31
pFTS −1.07 ± 0.08 −2.90 ± 0.07 0.94 −2.95 ± 0.16
p700 −1.07 ± 0.23 −2.85 ± 0.16 0.74 −2.89 ± 0.27
a
Range corresponds to the 95% confidence interval.
b
Slopes are not significantly different from −1.
c
The average intercept value, log C, was obtained by extrapolating each data point to the y-axis using a slope of −1 (see Section 2.6). Log C is
equivalent to the regressed intercept when the regressed slope is exactly −1.
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Table 2
Net US/SLS treatment times for samples treated to attain R values of 1.5 ± 0.6 kΩ·cm2. a
Skin Type n Time (min) b
hFTS 8 10.6 ± 8.8
h700 10 5.1 ± 2.6
h250 6 2.8 ± 2.8
pFTS 14 2.5 ± 0.7
p700 10 2.9 ± 1.7
a
We report the treatment times for a small subset of the range of R values investigated (compared to the range investigated that spanned two
orders-of-magnitude) in order to make useful statistical comparisons among the treatment times for the skin models. This range of R values was
attained in an in vivo clinical study (reported in ref. [22] as mean ± SD). Up to 45 seconds of US/SLS treatment time was required to attain this
range of R values in the clinical study [22]. However, it is important to note that the clinical ultrasonic skin permeation device was operated at a
frequency of 55 kHz. It has previously been shown that the treatment time required to obtain a desired R value varies with US frequency [32,41].
However, by varying US frequency and US/SLS treatment time until different skin samples reach the same skin electrical resistivity value, the skin
barriers are permeabilized to similar extents [18,32,41].
b
Range corresponds to mean ± SD for n samples.
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